GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuroscientific Biopharmaceuticals Ltd (ASX:NSB) » Definitions » Net Income Including Noncontrolling Interests

Neuroscientific Biopharmaceuticals (ASX:NSB) Net Income Including Noncontrolling Interests : A$0.76 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Neuroscientific Biopharmaceuticals Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Neuroscientific Biopharmaceuticals's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2023 was A$-1.23 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.76 Mil.

Neuroscientific Biopharmaceuticals Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Neuroscientific Biopharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuroscientific Biopharmaceuticals Net Income Including Noncontrolling Interests Chart

Neuroscientific Biopharmaceuticals Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Net Income Including Noncontrolling Interests
-1.66 -2.87 -3.18 -10.44 -1.07

Neuroscientific Biopharmaceuticals Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.73 -4.70 -3.06 1.99 -1.23

Neuroscientific Biopharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuroscientific Biopharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Neuroscientific Biopharmaceuticals's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuroscientific Biopharmaceuticals (ASX:NSB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuroscientific Biopharmaceuticals Ltd (ASX:NSB) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ASX:1AD ASX:ZLD ASX:MEM ASX:AVE ASX:ILA ASX:NC6 ASX:ACR ASX:EX1 ASX:BGT ASX:HXL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
85 Forrest Street, Suite 5, Cottesloe, Perth, WA, AUS, 6011
Website
https://www.neuroscientific.com
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.

Neuroscientific Biopharmaceuticals (ASX:NSB) Headlines

No Headlines